Model-informed development of a cost-saving dosing regimen for enfortumab vedotin.

ABSTRACT:

Aim

Enfortumab vedotin is an antibody-drug conjugate (ADC) that has been approved for locally advanced or metastatic urothelial cancer, as monotherapy and in combination with pembrolizumab, and has shown significant benefit in progression-free survival and overall survival for these patients. The economic burden of enfortumab vedotin hampers widespread patient access. The aim of this study was to develop a model-informed alternative dosing regimen that results in equivalent drug exposure while reducing the costs and prevent drug spillage.

Methods

Population pharmacokinetic modelling was used to simulate a dosing regimen leading to equivalent exposure by using the published population pharmacokinetic model in the registration reports. The alternative dosing regimen was based

SUBMITTER: Op 't Hoog CJ 

PROVIDER: S-EPMC11860999 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature